RxDoctor Payments Data

Randall Bell, MD

Pulmonary Disease · San Antonio, TXNPI 1780681403

Payments from drug & device makers

$38,088in general payments, 2019–2025

Across 962 payments — averaging $39.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$19K
  • GSK$4K
  • AstraZeneca$3K
  • Mylan Specialty L.p.$2K
  • Boehringer Ingelheim$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • plus $7K from 37 others

What the payments were for

  • Speaking & faculty fees$16,00042%
  • Travel & lodging$2,4977%
  • Food & beverage$19,56351%
  • Education$280%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,088 in reported general payments places this provider in the 85th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$313,467
Medicare patients
712
Services billed
3,380

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate120$1,585,274
Pirfenidone73$348,126
Trelegy ElliptaFluticasone/Umeclidin/Vilanter323$322,893
EsbrietPirfenidone21$212,849
Breztri AerosphereBudesonide/Glycopyr/Formoterol231$177,337
Dupixent SyringeDupilumab48$174,129
Fasenra PenBenralizumab25$143,540
Spiriva RespimatTiotropium Bromide81$76,421
Breo ElliptaFluticasone/Vilanterol89$56,019
NucalaMepolizumab13$47,955
Stiolto RespimatTiotropium Br/Olodaterol Hcl64$36,159
SymbicortBudesonide/Formoterol Fumarate105$32,822
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$23,596
Combivent RespimatIpratropium/Albuterol Sulfate22$22,313
DuleraMometasone/Formoterol27$16,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat$1,487$1,720,167287 claims
GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Arnuity Ellipta$3,948$455,724463 claims
Genentech USA, Inc.Esbriet$19,138$212,84921 claims
AstraZenecaBreztri Aerosphere, Symbicort$3,220$210,159336 claims
MerckDulera$48$16,82127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →